OncLive TV

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Shanu Modi, MD, discusses the significance of the FDA approval of the antibody-drug conjugate trastuzumab deruxtecan in patients with HER2-low breast cancer.

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

Sapna Patel, BA, MD, discusses the neoadjuvant administration of pembrolizumab in advanced melanoma.

Daniel P. Petrylak, MD, discusses enzalutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer.

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Moshe Ornstein, MD, MA, discusses toxicity concerns when treating renal cell carcinoma.

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Mark Yarchoan, MD, discusses the addition of durvalumab (Imfinzi) to gemcitabine and cisplatin in biliary tract cancer.

Javier Martin-Broto, MD, PhD, discusses future research directions of soft tissue sarcoma.

Alison K. Conlin, MD, discusses the practice-changing data of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Sameek Roychowdhury, MD, PhD, discusses the prevalence of FGFR mutations in intrahepatic cholangiocarcinoma.

Jennifer Keating Litton, MD, discusses research areas of interest in ESR1-mutated, endocrine receptor–positive, HER2-negative breast cancer.

Edward S. Kim, MD, MBA, discusses the role of biomarker testing in making treatment decisions for patients with solid tumors.

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Virginia G. Kaklamani, MD, discusses the use of adjuvant olaparib in germline BRCA1/2-mutant breast cancer.

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Edward S. Kim, MD, MBA, discusses the clinical implications of antibody-drug conjugates in HER2-positive solid tumors.

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.

Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.

Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.

Javier Martin-Broto, MD, PhD, discusses the current treatment landscape in the first-line setting for soft tissue sarcomas.

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Pedro C. Barata, MD, MSc, discusses the role of maintenance avelumab in advanced urothelial cancer.

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.